Nevertheless, over the treatment period, both AXA1125 and AXA1957 led to reductions in hepatic steatosis of −22.9% and −20.3%, respectively, and serum ALT levels of −21.9% and −20.6%, respectively, indicating a favorable impact on liver fat content and hepatocellular injury. Here, GPT is linked to fatty liver disease.